Lentinan for treatment of malignant pleural effusion:A meta-analysis of randomized controlled trials

OBJECTIVE: Meta-analysis of systematic review evaluated lentinan (LNT) alone or in combination with other drug treatment of malignant pleural effusion (MPE) the clinical efficacy and safety. METHODS: Pubmed, Cochrane Library, Embase, CBM, CNKI , VIP and Wanfang database system, a comprehensive collection of relevant LNT alone or in combination with other medications MPE controlled clinical studies. RESULTS: The systematic review of 17 randomized controlled trials included a total of 7,978 patients, of which 500 cases LNT group, cis platinum group of 478 cases. Meta analysis showed, LNT group was significantly better than the clinical efficacy of cisplatin group (OR = 3.68,95% CI = 2.75 ~ 4.94; P <0.00001); LNT group after treatment, Karnofsky score increased number of patients cisplatin were significantly more patients (OR = 3.79,95% CI = 2.46 ~ 5.84, P <0.00001), which reduces the number of patients and stable cisplatin group was significantly lower than in patients (OR = 0.41,95% CI = 0.21 ~ 0.78, P = 0.007; OR = 0.37,95% CI = 0.22 ~ 0.60, P <0.0001); LNT group gastrointestinal reactions, and hematologic toxicity was significantly reduced compared with cisplatin group (OR = 0.31,95% CI = 0.21 ~ 0.47, P <0.00001; OR = 0.49,95% CI = 0.28 ~ 0.84, P = 0.01). CONCLUSIONS: available evidence suggests that, LNT monotherapy or in combination with other medications MEP clinical efficacy and safety are excellent on cisplatin alone, can be widely used in clinical treatment of advanced malignant pleural effusion.